News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MissionTherapeutics Ltd Co-Founder and CSO Becomes an Associate Faculty Member at the Wellcome Trust Sanger Institute



4/8/2013 11:28:52 AM

Cambridge, UK – 8th April 2013 – MISSION Therapeutics (“MISSION”), the company focused on the discovery and development of modulators of deubiquitylating enzymes (DUBs) for the treatment of cancer, is pleased to announce the recent appointment of the Company’s co-founder and Chief Scientific Officer, Professor Steve Jackson as Associate Faculty Member at the prestigious Wellcome Trust Sanger Institute. Professor Jackson is a Fellow of both the Royal Society and the UK Academy of Medical Sciences, and since 1995 has held the Frederick James Quick Chair of Biology at the University of Cambridge, a post which he currently combines with Head of the Cancer Research UK Laboratories at the Gurdon Institute, Cambridge.

Professor Jackson takes a position within the Department of Human Genetics at the Sanger Institute, where his research will focus on the maintenance of genome stability. His research group based at the Gurdon Institute, University of Cambridge and the new complementary group at the Sanger Institute are focused on the mechanistic understanding of DNA repair and damage responses in normal and diseased cells. His Maintenance of Genome Stability team at the Sanger Institute will aim to understand precisely how cells respond to DNA damage. This research will provide new insights into human cell biology and human disease, and may identify opportunities for developing new diagnostic tools and therapeutic agents.

The post of Associate Faculty Member gives Professor Jackson access to the world class research of the Sanger Institute, allowing his research teams to collaborate with other Sanger Institute researchers and draw on the wealth of resources within the Institute, particularly in cancer genetics.

"We are delighted to welcome such a distinguished basic and translational researcher as Steve Jackson to our Associate Faculty – a cadre of researchers whose skills complement our own and with whom we can build new opportunities for genomic exploration," says Professor Michael Stratton, Director of the Wellcome Trust Sanger Institute. “Our collective aim is to build a portfolio of research that will contribute as rapidly as possible to therapeutic development and we very much look forward to achieving that goal with Steve.”

Dr Michael Moore, Chairman of the MISSION Board commented: “Steve’s appointment to the Associate Faculty position at the Sanger Institute is further testimony to his distinction and leadership position as a world-class scientist in the field of cancer genetics and of DNA repair. Steve’s contribution to the elucidation of disease mechanisms contributing to cancer and other disorders will stimulate the pursuit of new and more effective diagnostic and therapeutic approaches.”

About Wellcome Trust Sanger Institute

The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease. http://www.sanger.ac.uk/

About MISSION Therapeutics Ltd

MISSION Therapeutics is a private drug discovery company developing small molecule drugs targeting deubiquitylating enzymes (DUBs) involved in the cell’s DNA damage response, to treat cancer and other diseases. Its aim is to develop first-in-class DUB-modulating compounds to induce synthetic lethality, a powerful mechanism that selectively kills cancer cells.

The company has a novel DUB technology platform that integrates unique biology, screening and chemistry capabilities with cutting-edge, industry-leading ubiquitin activity assays. It has a number of promising, highly validated targets and small molecules at various stages of development, with strong potential to become first-in-class therapeutics. MISSION also has a pipeline agreement with the University of Cambridge and Cancer Research Technology that allows access to certain IP and know-how emerging from the academic work of Professor Steve Jackson’s laboratory.

MISSION Therapeutics was founded in 2011 by Professor Steve Jackson FRS, Dr Niall Martin, Dr Xavier Jacq and Dr Keith Menear, along with Cancer Research Technology and Cambridge University. MISSION has received £6 million in a Series A funding from a strong venture capital syndicate comprising Sofinnova Partners, Imperial Innovations, SR One and Roche Venture Fund and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit www.missiontherapeutics.com

About Gurdon Institute

The Gurdon Institute, part of the School of Biological Sciences in the University of Cambridge, was founded in 1989 to promote research in the areas of developmental biology and cancer biology, and to foster a rich and collaborative environment for independent research groups with diverse but complementary interests. http://www.gurdon.cam.ac.uk/

Contacts

College Hill Life Sciences

Tim Watson / Henry Stanley

MissionTherapeutics@collegehill.com

+44 (0) 20 7457 2020

MISSION Therapeutics

Dr. Niall Martin, COO

nmartin@missiontherapeutics.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES